Trium Capital’s AstraZeneca AZN Stock Holding History

Trium Capital’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-51,321	Closed	-$7.54M	–	57
2025 Q1	$7.54M	Buy	+51,321	New	+$7.43M	0.94%	14

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Sanders Capital West Palm Beach, Florida $83.9B AUM 37.89% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Trium Capital's AZN Position: Q2 2025 in Review

Trium Capital sold out of AstraZeneca (AZN) in Q2 2025, closing a stake of 51,321 shares — an estimated $7.54M sold.

Trium Capital first reported a position in AZN in Q1 2025 and held it in 1 quarter. The position peaked at $7.54M in Q1 2025. 1,222 funds tracked by Wall St. Rank hold AZN as of Q2 2025.

Trium Capital reported no remaining AstraZeneca position as of Q2 2025 after selling out during the quarter.
Trium Capital sold 51,321 AstraZeneca shares in Q2 2025, an estimated $7.54M.
Trium Capital first reported a position in AstraZeneca in Q1 2025 and held it in 1 quarter.
Trium Capital's AstraZeneca position peaked at $7.54M in Q1 2025.
1,222 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2025.

Based on Trium Capital's 13F filing for Q2 2025, filed 11 Aug 2025.